FDA ap­proves Lil­ly’s BTK in­hibitor Jaypir­ca for two more blood can­cers

The FDA grant­ed ac­cel­er­at­ed ap­proval to Eli Lil­ly’s Jaypir­ca for cer­tain pa­tients with chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, the In­di­anapo­lis-based phar­ma com­pa­ny an­nounced Fri­day evening.

Adult pa­tients who have re­ceived a pre­vi­ous BTK in­hibitor and a BCL-2 in­hibitor are el­i­gi­ble to re­ceive Jaypir­ca. While Lil­ly’s dai­ly pill is al­so a BTK in­hibitor, it binds re­versibly, un­like oth­er BTK in­hibitors, in­clud­ing Ab­b­Vie and John­son & John­son’s Im­bru­vi­ca, As­traZeneca’s Calquence and BeiGene’s Brukin­sa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER